These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12596751)

  • 1. Nondiabetic kidney disease.
    Goto A
    N Engl J Med; 2003 Feb; 348(8):762-3; author reply 762-3. PubMed ID: 12596751
    [No Abstract]   [Full Text] [Related]  

  • 2. [Blockade of the renin-angiotensin system. ACE inhibitors, angiotensin II antagonists or both?].
    Karlsen FM; Kamper AL
    Ugeskr Laeger; 2003 Oct; 165(42):4006-9. PubMed ID: 14610833
    [No Abstract]   [Full Text] [Related]  

  • 3. Proteinuria, a modifiable risk factor: angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs).
    Dykeman-Sharpe J
    CANNT J; 2003; 13(4):34-6; quiz 37-8. PubMed ID: 14753101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease.
    Weir MR
    Postgrad Med; 2009 Jan; 121(1):96-103. PubMed ID: 19179817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive therapy in the presence of proteinuria.
    Sarafidis PA; Khosla N; Bakris GL
    Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression.
    Bakris GL; Weir MR
    Postgrad Med; 2008 Apr; 120(1):33-42. PubMed ID: 18467807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial.
    Bakris GL; Ruilope L; Locatelli F; Ptaszynska A; Pieske B; Raz I; Voors AA; Dechamplain J; Weber MA
    J Hum Hypertens; 2006 Sep; 20(9):693-700. PubMed ID: 16710287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regarding: "Management of glomerular proteinuria: a commentary".
    Brenner BM
    J Am Soc Nephrol; 2004 May; 15(5):1354-5; discussion 1356-7. PubMed ID: 15100378
    [No Abstract]   [Full Text] [Related]  

  • 9. Angiotensin receptor blockers do not have an advantage over angiotensin-converting inhibitors [corrected].
    Harman-Boehm I
    Isr Med Assoc J; 2004 May; 6(5):296-8. PubMed ID: 15151373
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical use of evidence-based medicine: searching.
    Spier BJ; Feldstein DA
    WMJ; 2006 Jul; 105(5):9-11. PubMed ID: 16933405
    [No Abstract]   [Full Text] [Related]  

  • 11. [Kidney failure, proteinuria, and diabetic nephropathy].
    Collart F
    Rev Med Brux; 2003 Sep; 24(4):A257-62. PubMed ID: 14606290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical inquiries. Is combining ACE inhibitors and ARBs helpful or harmful?
    Chavey WE; Nashelsky J; Kilgore D
    J Fam Pract; 2004 Feb; 53(2):138-42. PubMed ID: 14764298
    [No Abstract]   [Full Text] [Related]  

  • 13. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises.
    Palmer BF
    Nephrol Dial Transplant; 2003 Oct; 18(10):1973-5. PubMed ID: 13679467
    [No Abstract]   [Full Text] [Related]  

  • 14. Progression of chronic kidney disease: can it be prevented or arrested?
    Jaber BL; Madias NE
    Am J Med; 2005 Dec; 118(12):1323-30. PubMed ID: 16378772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin system inhibitors in proteinuric chronic kidney disease.
    Hirsch S
    Compr Ther; 2009; 35(2):91-5. PubMed ID: 19618757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing hypertension using combination therapy.
    Frank J
    Am Fam Physician; 2008 May; 77(9):1279-86. PubMed ID: 18540493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
    Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; Larczyński W; Rutkowski B
    Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in slowing the progression of chronic kidney disease.
    Ripley E
    Am Heart J; 2009 Jun; 157(6 Suppl):S7-S16. PubMed ID: 19450722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.